In a phase 3 trial of 136 patients with active anterior noninfectious uveitis, dazdotuftide (TRS01) drops were inferior to prednisolone acetate for clearing anterior chamber cells at day 28 (48% vs 68%), but noninferior for flare and pain, with better IOP safety.
RCTn = 136
Chu et al. Dazdotuftide: Novel Treatment for Noninfectious Uveitis with Superior Intraocular Pressure Safety Profile: A Randomized Clinical Trial